ScienceDaily (Oct. 10, 2012) Whole genome sequencing -- spelling out all 3 billion letters in the human genome -- \"is an obvious and powerful method for advancing our understanding of pancreatic cancer,\" according to a new study from TGen, Mayo Clinic and Scottsdale Healthcare published October 10. <\/p>\n
The Translational Genomics Research Institute (TGen) demonstrated that the use of WGS \"represents a compelling solution to obtaining detailed molecular information on tumor biopsies in order to provide guidance for therapeutic selection,\" concluded the study published by the journal PLOS ONE. <\/p>\n
Examining three patients, the study spelled out the DNA of normal cells and compared that to the DNA of cells from biopsies of pancreatic adenocarcinoma (PAC), which makes up 95 percent of all pancreatic cancer tumors. Pancreatic cancer is the fourth leading cause of cancer death in the U.S. <\/p>\n
Using next-generation sequencing, the study generated an average of 132 billion mappable bases, or data points, for each patient, resulting in the identification of 142 cellular genetic coding events, including mutations, insertions and deletions, and chromosomal copy number variants. <\/p>\n
\"This study is the first to report whole genome sequencing findings in paired tumor\/normal samples collected from (three) separate PAC patients,\" said the report, which also was compiled with the collaboration of Mayo Clinic in Arizona, Arizona State University, and the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, which is a partnership between TGen and Scottsdale Healthcare. <\/p>\n
In all three case studies, the report found multiple potential therapeutic targets, highlighting the need to study the full spectrum of the genome and re-emphasizing the need to develop multiple avenues of therapeutics to match the specific medical challenges of each patient. <\/p>\n
\"Cancer, and specifically here pancreatic cancer, is a highly complex disease that ultimately will require a variety of treatment methods to control, and ultimately to cure,\" said Dr. Daniel Von Hoff, TGen's Physician-In-Chief, and Chief Scientific Officer for the Virginia G. Piper Cancer Center at Scottsdale Healthcare. <\/p>\n
\"This study shows that, as we continue to generate more information by sequencing the whole genomes of patients, we will continue to discover -- with ever more confidence -- the specific mechanisms that cause this cancer,\" said Dr. Von Hoff, one of the study's senior authors and one of the world's leading authorities on pancreatic cancer. <\/p>\n
\"We are very pleased to be working together with TGen in bringing hope and state of the art therapy to our patients at the Mayo Clinic Comprehensive Cancer Center,\" said Keith Stewart, M.B., Dean of Research at Mayo Clinic in Arizona, and the study's other senior author. <\/p>\n
In the case of Patient 1, for example, genes previously associated with PAC were identified, including BRCA2, TP53, CDKN2A, MYC, SMAD4 and KRAS. But the study also made new discoveries. \"Although BRCA2 mutations have been identified in PAC, the deletion we identify here in exon 10 of BRCA2 has not been previously reported,\" the study said. <\/p>\n<\/p>\n
Read the original here: ScienceDaily (Oct. 10, 2012) Whole genome sequencing -- spelling out all 3 billion letters in the human genome -- \"is an obvious and powerful method for advancing our understanding of pancreatic cancer,\" according to a new study from TGen, Mayo Clinic and Scottsdale Healthcare published October 10. Continue reading
\nFirst whole genome sequencing of multiple pancreatic cancer patients has been outlined<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"